Clinical Trial: Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Study Status: Completed
Recruit Status: RECRUITING
Condition: Chronic Lymphocytic Leukemia
Study Type: INTERVENTIONAL
Official Title: A Phase Ib Study Evaluating the Safety and Efficacy of Tafasitamab, Acalabrutinib, and Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia
Brief Summary:
This phase Ib trial tests the safety and effectiveness of tafasitamab, acalabrutinib, and obinutuzumab in treating patients with previously untreated chronic lymphocytic leukemia (CLL).CLL is a type of cancer that develops from a specific white blood cell called B cells or B lymphocytes.Tafasitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread.Acalabrutinib is in a class of medications called kinase inhibitors.It blocks a protein called BTK, which…
Read more